 "Capsules")
Ajanta Pharma was trading 4% lower at Rs 1,713, recovering 12% from its intra-day’s low on the BSE after the company clarified that there is no import alert by the US Food and Drug Administration (FDA) and the company continue to supply to US market.
The stock of pharmaceutical company hit an intra-day low of Rs 1,527, tanked 15% from its early morning high of Rs 1,804 on the BSE after the media reports suggested that Ajanta Pharma has received import alert from USFDA for its Paithan unit at Aurangabad.
The counter has seen huge trading volumes with
The stock of pharmaceutical company hit an intra-day low of Rs 1,527, tanked 15% from its early morning high of Rs 1,804 on the BSE after the media reports suggested that Ajanta Pharma has received import alert from USFDA for its Paithan unit at Aurangabad.
The counter has seen huge trading volumes with
